initi buy price target
diversifi medic devic compani
monitor cerebr spinal fluid precis tool instrument
codman specialti surgic css total sale segment shoulder
hernia breast reconstruct solut privat label product
orthoped tissu technolog ott total sale segment
later stage integr codman acquisit expand
geograph footprint augment optim distribut channel
introduc new product drive organ growth
headwind subsequ stock pullback buy opportun
stock pull back vs
equip suppli sinc earn releas headwind
codman day countri slower expect ramp orthoped
expand sale forc result lower guidanc
view headwind temporari sinc take oper
day countri sometim repres codman sale
orthoped take quarter ramp could
mitig higher growth segment
growth organ css grow ott
organ codman acquisit well increment hire
increas sale footprint fte ex-u
target sell focu term ebitda margin forecast
bp improv gm elev favor mix
obsolesc low margin product increasingli autom manufactur
improv design manufactur movement away transit
servic manufactur agreement johnson johnson nr
model leverag associ w/ erp consolid central
back offic oper low cost locat better overhead absorpt
aforement item contribut ep growth across
valuat catalyst risk pt deriv appli
ev/sal multipl revenu estim in-lin
mean/median peer compar ev/ebitda basi
appli multipl ebitda estim
peer mean/median multipl impli valuat
catalyst includ duragen launch japan quarterli earn
tr target
tabl content
page
valuat scenario analysi bull strh base bear case nutshel diversifi growth margin expans opportun highlight forecast continu top-lin growth margin improv ott segment schemat valuat analysi overview css organ growth specialti surgic css segment total sale neurosurg precis tools/instru specialti surgic css segment neurosurgeri precis tool instrument overview specialti surgic css segment codman acquisit overview overview ott organ growth tissu technolog ott segment extrem orthoped tissu technolog ott segment divest consider acquisit histori compens biographi board member institutional/insid holder statement model sheet model model integra lifesci hold corpor
growth base case
assumpt driven better expect
market growth greater anticip
impact augment sell forc
perhap especi ex-u better
case project css ww sale
organ compound-annual-growth-rate ott ww sale
scenario assum higher
vs base scenario due
higher product volum emphasi
higher margin regen product
expect cost effici
realiz exit transit agreement
lower oper
expens vs base case
arriv per share valu appli
ev/sal multipl
sale altern appli
ev/ebitda multipl
base case assum revenu
growth organ driven
diversifi mix product across grow
introduct
geograph expans direct
sale forc forecast css ww sale
organ compound-annual-growth-rate ott ww
sale organ compound-annual-growth-rate
forecast assum expand
vs ebitda
margin improv vs
increas driven
exit transit agreement
improv product mix emphasi
pt deriv appli
ev/sal multipl revenu
estim in-lin
peer group compris compani
similar size growth rate
ev/ebitda basi appli
multipl ebitda estim
aforement peer
group suggest potenti upsid pt
better expect execut
bear case scenario assum
revenu growth
base case assumpt driven slower
expect augment sale
increas competit blunt
effect new product introduct bear
case project css ww sale
organ compound-annual-growth-rate ott ww sale
scenario assum bp
lower vs base case scenario
due lower product volum
oper expens
arriv per share valu appli
ev/sal multipl
sale altern appli
ev/ebitda multipl
page
call nutshel diversifi growth margin expans opportun
manufactur sell medic instrument devic equip codman specialti surgic precis tool instrument dural
repair neuro critic care orthoped tissu technolog extrem orthoped wound care surgic reconstruct busi segment
forecast report growth organ period
driven diversifi product mix segment growth opportun
rang low singl low doubl digit combin new product
introduct expans foreign market addit
process integr codman acquisit
expand geograph footprint significantli increas sale
forc ex-u optim
distribut channel special sale focu
term ebitda margin forecast bp improv
time-frame contribut favor mix obsolesc
design manufactur movement away transit servic
manufactur agreement leverag associ
erp consolid central back offic oper low cost
contribut estim ep growth across
panta launch us
duragen launch japan
codman tsa expir western european countri
codman tsa expir japan
pt deriv appli ev/sal
multipl revenu estim in-lin
mean/median forward ev/sal peer
ev/ebitda basi appli multipl
ebitda estim peer mean/median
page
revenu forese report sale growth organ time-frame base global channel expans increas sale
margin project gross margin improv next year driven faster growth higher
margin regen wound care surgic reconstruct dural graft nerv repair product gm rang non-oem collagen improv design
manufactur elimin lower margin sku full assumpt codman manufactur robot manufactur collagen base product
virtual regen portfolio term ebitda forecast bp improv time-frame addit
contribut exit transit servic agreement leverag erp consolid central back offic oper low cost
locat better overhead absorpt
estim gener gener improv codman transit agreement
begin roll capital-expenditure invest decreas due complet mansfield massachusett codman facil
debt financ amend exist credit facil may total avail facil remain consist revolv line
credit increas term loan decreas credit facil matur date also extend month may
iart pro forma net debt bank leverag ratio maximum allow per credit agreement
equiti financ may complet follow-on offer common stock net proce use pay debt
page
yr compound-annual-growth-rate except ebita ebitda incl ebitda debt integra lifesci hold corpor
segment schemat display right show constant
currenc organ segment growth assumpt period
period assum codman specialti
surgic segment css grow compound-annual-growth-rate wherea orthoped
tissu technolog ott segment grow aggreg
assum organ growth rate lower
rang manag expect set investor day
shown schemat presumpt us growth
approxim ex-u growth influenc heavili
us-centr concentr fast grow wound care busi
call manag advis street model
organ growth around grow sale momentum across
could allow us increas mid-term revenu expect
within css sale presum advanc
csf manag show fastest growth
respect princip basi new product introduct
includ cusa famili tissu ablat product new rf
gener advanc csf shunt within dural access
repair assum around growth thought
duras franchis weather competit threat
lower price synthet sealant part mani neuro case still
within ott sale expect solid growth
rel small ankl compound-annual-growth-rate shoulder arthroplasti
compound-annual-growth-rate franchis solid growth acut outpati
wound care product heavili leverag iart capabl
collagen formul compound-annual-growth-rate also assum privat label
princip base upon suppli collagen base compon
manufactur grow high singl digit rate within
segment ott nerv repair busi
think could provid nice sourc growth increas
sale channel focu reflect mid-singl digit growth assumpt
surgic reconstruct segment primarili surgimend new
indic breast market shift away synthet hernia
could result potenti upsid estim
page
schemat codman specialti surgic segmentcss revenuesprecis tool access spinal fluid csf rate yoy precis tool access spinal fluid csf tissu technolog segmentott revenuesankl reconstruct acut wound rate reconstruct acut wound revenuestot portfoliotot wound recon privat wound recon privat label integra lifesci hold corpor
pt deriv appli ev/sal multipl revenu estim in-lin mean/median forward
ev/sal peer peer group compris compani similar size growth rate
ev/ebitda basi appli multipl ebitda estim peer mean/median yield
valuat better expect mid-term execut could result multipl expans rel embed price target
compani document factset strh estim note base strh estim other consensu
page
companypric ofmarketrevenueebitdarevenu growthev/salesev cap medic medic medic compani medic hold vascular medic system medic hold targetenterpris valu ev sale valuationiart revenu ev/revenu enterpris valu debt equiti share valu per ebitda valuationiart ebitda ev/ebitda enterpris valu debt equiti share valu per integra lifesci hold corpor
arriv pt dcf requir employ discount rate termin growth rate high discount
rate low termin growth rate requir match price target reflect potenti upsid better expect mid-
page
depr stock compless capit chang work free free growth npv termin excess secur mv debt sensit tableless mv prefer equiti share outstand valu per growth integra lifesci hold corpor
codman relat risk current work complet integr codman acquisit delay exit transit
servic manufactur agreement underleverag newli expand sale forc could lead lower expect
gross/ebitda margin under-perform long-term accret ep goal exampl risk pertain
announc day countri busi significantli lag transit
delay margin expans failur achiev higher product margin product mix faster growth profit product
obsolesc low margin product improv design manufactur factori autom may hinder gross margin progress
untoward impact upon gener capac
product competit price pressur competitor may enter iart hyperbranch recent purchas buy
exist market may activ induc price pressur neg impact revenu momentum
 risk histor grown compani overpay futur target fail execut
synergy/integr goal financi result could neg impact
difficulti model end market render stock brittl difficult model iart end-market precis
outpati wound care could render stock good last coupl quarter creat potenti volatil stock price
page
page
codman specialti surgic css segment total sale neurosurg precis tools/instru
codman specialti surgic sub-seg sale
management repres total sale hold strong share posit
dural access repair total sale sale
main product duragen collagen matrix graft supplier contract
 duras synthet absorb hydrogel acquir covidien buy
use prevent cerebrospin fluid csf leak cranial
spinal surgeri approxim market opportun
duras face competitor pressur hyperbranch recent acquir
promot trial lower price cranial
indic duras also spine indic believ
repres product use abl lock longer term
contract custom retain share slightli lower price go
forward believ face increas competit pressur syk
integr hyperbranch product portfolio
year growth expect iart dural access repair segment grow
high end market growth princip due enhanc sale
duragen duras higher rep count geograph expans japan
addit plan invest clinic data support
duras polyethylen glycol base product efficaci
plasma-bas sealant sutur alon
page
salescodman specialti surgic access perforatorsstrips/pattiesadvanc tissu ablationelectrosurgeryversatruneuro kitsevdslicox oxygen monitoringicp expressdirectlink icp monitor interfacescerebr spinal fluid csf shuntshakim valvecerta plusbactis antimicrobi cathetersfix shuntsprecis tool cranial stabil licens crwspecialti instrumentsgener instrumentslight acquir codman productsorthoped tissu technolog tool instrument access repair energi monitor manag integra lifesci hold corpor
advanc energi total sale sale
compos cusa clariti platform use ultrason tissu ablat larg instal base cusa particularli use
remov fibrou materi brain surgeri electrosurgeri includ bipolar gener bipolar forcep versatru prior
acquisit codman develop new rf platform segment compris roughli dispos capit equip
defin market approxim
mid high singl digit year growth believ advanc energi one largest growth segment next year grow
market low mid singl digit estim base cusa clariti growth on-going launch japan
receiv regulatori approv futur anticip launch brazil china combin multi-year upgrad featur
develop plan addit procedures/appl electrosurgeri new platform launch earli
note cusa clariti gener higher gross margin legaci product due improv design manufactur higher asp
neuro monitor total sale sale
includ product extern ventricular drainag evd fix pressur shunt licox icp monitor use monitor brain oxygen
partial pressur intra-crani pressur respect manag believ market approxim annual
mid singl digit year growth expect growth compound-annual-growth-rate slightli market growth opportun new
product launch cerelink eu us japan australia brazil directlink brazil china
cerebr spinal fluid csf manag total sale sale
product use manag product excess csf fix pressur shunt programm shunt hakim valv bactis cathet
appli antimicrobi treatment neuro monitor shunt manag believ market approxim
market growth model compound-annual-growth-rate segment due appeal codman portfolio programm shunt gain
popular rel legaci fix shunt kind histor sold
precis tool instrument piec css sale sale
global player precis instrument surgical/light busi span mani treatment set rel sedat
segment unremark innov
growth project expect introduc new higher end specialti product mayfield cranial fixat led light system
page
codman acquisit acceler neurosurgeri segment year codman acquisit carve-out help expand
iart neurosurgeri portfolio becom player neurosurgeri acquisit increas total intern revenu
pre-acquisit time augment intern sale forc take much
bigger presenc japan china leverag addit pull orthoped tissu technolog product
exit tsa tma year provid margin uplift exit major transit servic
manufactur agreement relat codman acquisit stage next year final servic agreement
expir approxim month condit regulatori hurdl think exit agreement provid
increment gross margin sg uplift time
first transit servic agreement tsa expir end repres market alreadi good
geograph footprint codman us canada australia new zealand constitut codman revenu
assum custom servic order oper addit china tsa agreement end one year ahead schedul
repres revenu compani transit itali mexico therebi transit ww codman
transit manufactur agreement tma expir took full oper control manufactur facil locat
switzerland produc major hydrocephalu product transit jnj sap system
first half exit tsa cover western europ countri includ franc germani uk
cumul leav ww codman revenu transit japan expect transit
last tma necessit carv exist product line jnj exist manufactur facil locat raynham
massachusett move recent convert facil locat mansfield massachusett accord manag manufactur
may begin transfer pass regulatori inspect complet may take least month
day countri note call announc day distributor non direct countri approxim countri
includ china nordic czech republ slovakia brazil repres around revenu codman sale
experienc doubl digit sale declin due lack focus/distributor defect compani begin take control countri
point plan stabil oper either closer manag exist distributor and/or replac
regulatori mandat divestitur help close codman deal compli feder trade commiss anti-trust author
spain agre divest follow babi nr camino intracrani pressur icp monitor us right
fix pressur shunt portion neurosurgeri asset acquir codman
page
page
orthoped tissu technolog sub-seg sale
extrem orthoped sale compound-annual-growth-rate
recommit metal extrem orthoped segment boost us salesforc
wound reconstruct product respons previous dilut sell effort
ankl arthroplasti current third market share sale fix bear ankl
product cadenc salto talari expect ankl market sustain grow doubl
digit part due displac ankl fusion recent new xt total ankl revis system
launch us option acquir salto talari ex-u intern right
tornier sinc merg wright medic nr exercis model compound-annual-growth-rate
shoulder arthroplasti sale iart titan shoulder system use total shoulder
hemiarthroplasti current small particip us shoulder market grow
around link sold distributor model yet complet offer
 stemless shoulder anticip fill gap larg intern also hope
introduc pyrocarbon bear surfac may reduc joint wear although product introduct time
yet articul model slightli market growth franchis
lower extrem segment compos commod fusion/fractur
sale nerv tendon regen product aggreg busi declin
mid high singl digit hope increas sale focu help commod metal
segment well nerv repair product compani believ highli competit
plan introduc new panta product fusion arthrodesi nail ankl
current standard care treat advanc ankl arthriti
extrem orthoped realli remain seen whether increas sale focu
concert effort enabl segment flourish face stiff competit purer play
page
codman specialti surgic orthoped reconstruct reconstruct label salesorthoped tissu anklelow extremitynerv tendonsalto ankletitan shoulderupp extremityxt ankl revis systemwound reconstruct reconstruct acut bilay wound matrixflow wound matrixintegra dermal regener templateintegra wound matrixintegra wound matrix thin mesh bilay wound matrixmesh dermal regener templateprimatrixprimatrix agadvanc wound outpati amnioexcelamnioexcel plusmedihoneyomnigraftprimatrixtot contact cast tcc systemsurg revize-xsurgimendsurgimend mpsurgimend prsprivat dental integra lifesci hold corpor
wound reconstruct total sale sale forecast growth
extens leverag expertis collagen process make multipl product use acut inpati outpati
wound care space acquisit derma scienc secur access amniot regen product use
extens product mix outpati set well medihoney debrid prepar tcc-ez off-load
boot diabet foot ulcer iart strategi augment acut outpati
us dedic rep compani doesnt separ report acut outpati chronic wound sale
product use treat acut wound burn trauma limb salvag reconstruct highli prepar collagen provid
backbon product serv bio-absorb tissu ingrowth scaffold product also frequent employ outer
silicon barrier allow proper fluid balanc provid barrier infect use neg pressur wound
sale growth expand sale forc rep product launch integra dermal regener templat idrt
singl layer thin japan capit greater clinic awar potenti limb salvag reconstruct
outpati wound estim address segment
product use prepar treat protect chronic wound venou leg ulcer pressur ulcer diabet foot ulcer
portfolio inclus regen product omnigraft primatrix amnioexcel well medihoney
tcc-ez offload boot time derma scienc acquisit medihoney tcc-ez combin sale
key focu busi evid develop remain outpati formulari shift payment paradigm fee
servic episod care would revers econom disadvantag key product omnigraft requir
one two applic
surgic reconstruct total sale sale growth forecast
rel newer market primari product surgimend acquisit neonat acellular collagen
mesh good tensil strength despit poros use complex hernia repair market low growth
synthet domin breast reconstruct market ou indic current pursu us indic
clinic trial use newli devis pre-pector procedur believ increas direct us sell forc
fte well evid develop demonstr superior rel synthet hernia better outcom associ
pre-pector approach breast key success factor segment
privat label total sale sale project growth
iart regen dental collagen plug rebrand sold major medic technolog compani oper end market
compet orthoped spine dental product usual made order safeti stock privat label
gener gross margin point lower corpor averag higher ebitda margin due limit op-
ex busi exclus leverag iart collagen scienc expertis benefit new robot lower cost
collagen process plant new jersey accommod extens growth across iart collagen base product
page
 divest consider
iart criteria acquisit take consider product and/or technolog would increas market share build product scale
note manag affirm signific acquisit great major codman tsa expir
moment success execut codman acquisit strategi importantli built upon sale forc geograph
expans manag top prioriti said iart growth histor reliant given senior manag
background procliv expect hefti contribut inorgan growth futur although reflect project
strateg opportun consider main busi leg would consid neurosurgeri
extrem orthoped regen codman acquisit catapult neurosurgeri segment market leader
believ focu primarili increas market leadership posit extrem orthoped regen busi
potenti increas extrem orthoped market leadership within ankl market player shoulder divis acquisit
opportun exist build portfolio new product and/or licens note exercis right acquir ex-u
salto tornier manag commit complet acquisit
regen opportun add new product manag comment mani technolog opportun
ad exist portfolio market exist sale forc
neurosurgeri current scale codman acquisit rais neurosurgeri market posit ad new
product line geograph expans distribut neurosurgeri current scale result small tuck-in technolog deal
would current consid local distributor and/or new technology/licens
opportun exist increas gross margin portfolio sku optim discontinu and/or spin unprofit
product line exampl spun spine busi seaspin nr
product line within precis tool instrument busi segment would also consid divest
commod type growth product includ dental product acquir codman
product acquir derma scienc commod type product wound care gauz bandag low margin
manufactur china sold distributor product high list divestitur discontinu
page
success histori acquir success integr mani smaller busi across histori believ
like continu pursu opportunist tuck-in build relev scale augment sustain organ growth goal
global growth close codman neurosurgeri acquisit make global leader neurosurgeri increas
intern employe head count especi japan/china employe
manag project intern sale world-wide sale acquisit addit ex-
us distribut capabl like anoth focu
page
announc dateclos datetargetfirm typetransact valu revenu ltm theken famili famili compani help form integra new spine neurosci pti ltd australia new integra scientif manufactur tabl mount retractor use varieti spinal technolog minim invas motion preserv treatment spinal allyn inc surgic headlight includ luxtec surgic headlight includ integra surgic product distribut hardwar biolog spinal fixat orthoped integra extrem platform complementari implant product shoulder elbow wrist hand foot medic devic compani meet clinic need injuries/diseas foot surgic covidien confluent surgic develop dural repair surgic sealant adhes barrier product help expand integra neurosurgeri growth xome instrument sa buy help expand integra manual ent laparoscopi instrument product line enabl manufactur ventur ii dba metasurg foot ankl product implant system foot bioscienc biolog product soft tissu repair reinforc reconstruct deal occur tandom purchas sister compani tei medic integra product offer support cellular repopul revascular process deal occur tandom purchas sister compani tei right salto talari xt futura tornier us right expand lower extrem product portfolio includ option purchas intern right product itali tekm neurosurgery/neurotrauma focu support growth codman specialti surgic scienc complementari wound care product includ amniot tissue-bas product help expand integra regeneratvi technolog neurosurgeri busi johnson johnson codman neurosurgeri busi expand neurosurg product medic system develop softwar solut medic asset manag integra lifesci hold corpor
manag compens biographi board member
chang control compens
execut compens appear align sharehold interest compens determin compens committe meant
emphas pay-for-perform cultur
annual cash bonus weight toward specif financi metric explicitli defin target revenu adjust
ebitda oper compens committe allow neg discret reduc
award base weight toward financial/quantit metric toward qualit measur explicit financi target
outlin proxi weight adjust revenu adjust ebitda oper
one-tim bonu modifi appli integr codman neurosurgeri weight toward close deal earli toward
achiev revenu day countri decreas level
annual equiti award compris perform stock unit non-qualifi stock option restrict stock award focu
grant vest better encourag retent long-term share ownership
chang control event chang control addit termin without caus resign good reason doubl trigger
neo receiv cash sever base salari bonu pro rata bonu base compani perform along continu health/oth
benefit acceler vest stock options/oth grant
ceo presid peter arduini join integra lifesci presid serv presid ceo sinc previous
presid medic deliveri baxter healthcar work gener electr healthcar procter gambl mr arduini also
serv board director bristol-my squibb advam medic devic innov consortium nation italian american
foundat earn bachelor degre market susquehanna univers master manag northwestern univers
chief scientif offic kenneth burhop phd serv cso sinc join integra cso sangart also spent year
baxter healthcar multipl leadership role across baxter pharmaceut technolog medic deliveri divis dr burhop receiv ba
degre zoolog univers wisconsin-milwauke ms phd veterinari scienc univers wisconsin-madison
cfo glenn coleman serv cfo sinc join integra previous mr coleman work vice presid financ corpor
control well multipl financ execut posit alcatel-luc receiv bachelor degre montclair state
univers
board member includ stuart essig phd chairman md prettybrook partner peter arduini presid ceo integra keith bradley phd
director barbara hill oper nexphas capit lloyd howel jr cfo treasur booz allen hamilton
donald morel jr phd former ceo west servic raymond murphi former svp treasur time warner christian
schade presid ceo richard caruso phd founder integra chairman emeritu
note richard gorelick retir receiv board-approv payment compani document strh analysi
page
namecash severancecontinu health benefitsacceler stock optionsacceler grantsfees/interesttotalpet davi awardsopt awardsnon-equ incent compensational compensationtotalpet davi integra lifesci hold corpor
factset strh estim
top
top
growth fund
compani
top insid
outstand
share
page
page
except per share specialti orthoped tissu technolog consolid gross research total oper oper incom adj interest incom expens net interest pre-tax incom tax tax incom continu loss discontinu oper net tax net incom ep ebitda incl adjust ebitda excl expens margin analysi margin oper ebitda margin incl ebitda margin excl profit expens growth analysi yr/yr codman specialti surgic specialti surgic specialti surgic tissu technolog tissu technolog tissu technolog revenu organ adj acq cc revenu revenu oper incom ebitda incl integra lifesci hold corpor
page
integra lifesciencessuntrust robinson humphreybal sheet modelmed technolog cash restrict cash cash equivalents- short-term investments- account receiv defer tax prepaid expens current current asset discontinu total current properti equip intang asset defer tax long term investments- non-curr asset discontinu total borrow senior credit convert securities- account payabl defer accru short-term portion conting consideration- accru expens current current liabil discontinu total current long-term borrow senior credit long-term convert defer tax long-term liabil discontinu total common addit paid treasuri accumul comprehens incom accumul total stockhold total liabil stockhold integra lifesci hold corpor
page
integra lifesciencessuntrust robinson humphrey modelmed technolog activ net loss discontinu oper net depreci non-cash impair defer incom tax non-cash valuat allowance- excess tax benefit stock-bas compens arrangements- share-bas amort debt issuanc non-cash interest realiz loss sale sale short-term investment- loss dispos properti divestitur business- chang fair valu conting consider bargain purchase- payment accret interest- chang oper asset liabil account prepaid expens current non-curr account payabl accru expens current defer non-curr net cash provid oper activ continu net cash use oper activ discontinu net cash use oper invest activ chang restrict cash- proce sale short-term investments- proce note receivable- use busi acquisit net cash receiv busi acquisit purchas price adjustment- purchas properti proce sale properti equipment- proce divestitur business- chang intang long term investments- net cash use invest activ discontinu net cash use invest financ activ borrow senior credit repay senior credit net cash paid financ liabil busi acquisition- net cash paid conting consideration- proce issuanc common stock net issuanc costs- distribut seaspine- payment liabil compon convert notes- payment capit leas debt issuanc proce exercis stock excess tax benefit stock-bas compens arrangements- tax paid net equiti net cash use provid financ exchang rate chang cash cash net chang begin end free integra lifesci hold corpor
manufactur sell medic instrument devic equip codman
specialti surgic precis tool instrument dural repair neuro critic care orthoped
forecast report growth organ css grow ott
organ codman acquisit well increment hire increas sale footprint
fte ex-u target sell focu term
ebitda margin forecast bp improv gm elev favor
mix obsolesc low margin product increasingli autom manufactur improv design
manufactur movement away transit servic manufactur agreement
johnson johnson nr model leverag associ w/erp consolid
central back offic oper low cost locat better overhead absorpt
aforement item contribut estim ep growth across
valuat risk
pt deriv appli ev/sal multipl revenu estim
in-lin mean/median peer compar ev/ebitda
basi appli multipl ebitda estim peer
mean/median multipl impli valuat risk includ codman integr risk
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
page
